¼¼°èÀÇ È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀå ±Ô¸ð : Ä¡·á À¯Çüº°, ¾àÁ¦ À¯Çüº°, Åõ¿© °æ·Îº°, ÀûÀÀÁõº°, À¯Åë ä³Îº° ¿¹Ãø(2024-2032³â)
Neutropenia Treatment Market Size - By Treatment Type, Drug Type, Route of Administration, Indication, Distribution Channel, Global Forecast, 2024 - 2032
»óǰÄÚµå : 1485257
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2024³â 03¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 170 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 7,017,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,753,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 12,081,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

È£Áß±¸°¨¼ÒÁõ Ä¡·á½ÃÀåÀº ¾Ï, ÀÚ°¡¸é¿ªÁúȯ, °¨¿°Áõ µî È£Áß±¸°¨¼ÒÁõÀ» µ¿¹ÝÇÏ´Â °æ¿ì°¡ ¸¹Àº ÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ °ßÀεǾî 2024³âºÎÅÍ 2032³â¿¡ °ÉÃÄ CAGR 4.1% ÀÌ»óÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

WHO¿¡ µû¸£¸é 2022³â¿¡ »õ·Î ¾ÏÀ¸·Î Áø´Ü¹ÞÀº ȯÀÚ´Â ¾à 2,000¸¸¸í, »ç¸ÁÀÚ¼ö´Â 970¸¸¸íÀ̾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±âº» ÁúȯÀÇ ÀÌȯÀ²ÀÌ ¼¼°èÀûÀ¸·Î »ó½ÂÇϰí Àֱ⠶§¹®¿¡ È£Áß±¸°¨¼ÒÁõÀÇ Ä¡·á¸¦ ÇÊ¿ä·Î Çϴ ȯÀÚ¼öµµ »ó´çÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á±â¼ú°ú ÀǾàǰ °³¹ßÀÇ Áøº¸·Î È¿´É°ú ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀÌ °³¼±µÈ »õ·Î¿î Ä¡·á¹ý°ú Ä¡·á¹æ¹ýÀÌ µµÀԵǰí ÀÖ½À´Ï´Ù.

³ëÀεéÀº ³ëÈ­¿¡ µû¸¥ ¸é¿ª°èÀÇ º¯È­¿Í ¸¸¼ºÁúȯÀÇ À¯º´·üÀÌ ³ô¾Æ È£Áß±¸°¨¼ÒÁõ¿¡ °É¸®±â ½±°í È£Áß±¸°¨¼ÒÁõ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ È£Áß±¸°¨¼ÒÁõÀÇ Á¶±â ¹ß°ß°ú °ü¸®ÀÇ Á߿伺¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö¸é ÀÇ·á ¼­ºñ½º¿Í Áø´Ü¿¡ ´ëÇÑ Á¢±Ù¼º Çâ»ó°ú ÇÔ²² ȯÀÚÀÇ Áø´Ü·ü°ú Ä¡·á¸¦ Ãß±¸ÇÏ´Â ÇൿÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù.

È£Áß±¸ °¨¼ÒÁõ Ä¡·á ½ÃÀåÀº Ä¡·á À¯Çü, ¾à¹° À¯Çü, Åõ¿© °æ·Î, ÀûÀÀÁõ, À¯Åë ä³Î, Áö¿ªÀ¸·Î ±¸ºÐµË´Ï´Ù.

ÀûÀÀÁõº°·Î´Â Ư¹ß¼º È£Áß±¸°¨¼ÒÁõÀÌ 2024-2032³âÀÇ CAGR 4%·Î ¾÷°è¸¦ °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç ¿øÀÎÀ» È®ÀÎÇÒ ¼ö ¾ø´Â È£Áß±¸ ¼öÀÇ °¨¼Ò¸¦ Ư¡À¸·Î ÇÕ´Ï´Ù. ±Ùº» ¿øÀÎÀ» ¾Ë ¼ö ¾ø±â ¶§¹®¿¡ °¨¿°ÀÇ À§ÇèÀ» ÁÙÀ̰í ȯÀÚÀÇ QOLÀ» Çâ»ó½ÃŰ´Â Áõ»ó °ü¸®¿Í Áö¿ø ¿ä¹ýÀÌ Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÇÇÐ ¿¬±¸¿Í ¸é¿ª°èÀÇ ÀÌÇØÀÇ Áøº¸¿¡ ÀÇÇØ Ư¹ß¼º È£Áß±¸°¨¼ÒÁõÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÒ °ÍÀ¸·Î ±â´ëµÇ´Â Ç¥Àû Ä¡·áÁ¦³ª ¸é¿ªÁ¶ÀýÁ¦°¡ °³¹ßµÇ°í ÀÖ½À´Ï´Ù.

¾àÁ¦À¯Çüº°·Î º¸¸é, ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀº ¼±¹ßǰÀÇ »ý¹°ÇÐÀû Á¦Á¦¸¦ ´ëüÇÏ´Â ºñ¿ë È¿À²ÀûÀÎ ´ëüǰÀ» Á¦°øÇϱ⠶§¹®¿¡ 2024³âºÎÅÍ 2032³â¿¡ °ÉÃÄ È£Áß±¸°¨¼ÒÁõ Ä¡·á ½ÃÀåÀÇ CAGR ´Â 4.8%°¡ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼°è °Ç°­ °ü¸® ½Ã½ºÅÛÀÌ È¯ÀÚÀÇ Äɾ ¼Õ»ó½ÃŰÁö ¾Ê°í ºñ¿ëÀ» ¾ïÁ¦ÇÏ·Á°í ½ÃµµÇÏ´Â µ¿¾È ¹ÙÀÌ¿À ½Ã¹Ð·¯ ÀǾàǰÀÇ Àú·ÅÇÑ °¡°Ý°ú °¡¿ë¼ºÀÌ È£Áß±¸ °¨¼ÒÁõ Ä¡·á °èȹ¿¡ ´ëÇÑ ¹ÙÀÌ¿À ½Ã¹Ð·¯ ÀǾàǰÀÇ Ã¤¿ëÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀº ±âÁØ »ý¹°ÇÐÀû Á¦Á¦¿Í µ¿µîÇÑ È¿´É ¹× ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» ÀÔÁõÇϱâ À§ÇØ ¾ö°ÝÇÑ ±ÔÁ¦ ´ç±¹ÀÇ Á¶»ç¸¦ ¹Þ°í ÀÖÀ¸¸ç, ÀÇ·á Á¾»çÀÚ¿Í È¯ÀÚ¿¡°Ô ½Å·Ú¸¦ ÁÝ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ È£Áß±¸°¨¼ÒÁõ Ä¡·á»ê¾÷ ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 4.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áß±¹°ú Àεµ¿Í °°Àº ±¹°¡¿¡¼­ °Ç°­ °ü¸® ÀÎÇÁ¶ó¸¦ °³¼±Çϰí ÀÇ·áºñ¸¦ ´Ã¸®¸é È£Áß±¸ °¨¼ÒÁõÀÇ Áø´Ü°ú Ä¡·á¿¡ ´ëÇÑ Á¢±ÙÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á Á¾»çÀÚ¿Í È¯ÀÚ °£ È£Áß±¸ °¨¼ÒÁõ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ´Â °Í°ú ÀÇÇÐ ¿¬±¸¿Í Ä¡·á¹ýÀÇ Áøº¸°¡ ÇÔ²² ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ½ÃÀå È®´ë¸¦ ´õ¿í ÀÚ±ØÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ã߰衤¿¹Ãø : Ä¡·á À¯Çüº°(2018-2032³â)

Á¦6Àå ½ÃÀå Ã߰衤¿¹Ãø : ¾àÁ¦ À¯Çüº°(2018-2032³â)

Á¦7Àå ½ÃÀå Ã߰衤¿¹Ãø : Åõ¿© °æ·Îº°(2018-2032³â)

Á¦8Àå ½ÃÀå Ã߰衤¿¹Ãø : ÀûÀÀÁõº°(2018-2032³â)

Á¦9Àå ½ÃÀå Ã߰衤¿¹Ãø : À¯Åë ä³Îº°(2018-2032³â)

Á¦10Àå ½ÃÀå Ã߰衤¿¹Ãø : Áö¿ªº°(2018-2032³â)

Á¦11Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

JHS
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Neutropenia treatment market is anticipated to grow at over 4.1% CAGR between 2024 and 2032, driven by the increasing prevalence of conditions, such as cancer, autoimmune disorders, and infectious diseases, which are often associated with neutropenia. As per WHO, in 2022, there were approximately 20 million newly diagnosed cancer cases and 9.7 million fatalities. As the incidence of these underlying conditions is rising globally, there is a corresponding increase in the number of patients requiring neutropenia treatment. Additionally, advancements in medical technology and drug development have led to the introduction of novel therapies and treatment modalities for offering improved efficacy and safety profiles.

As older adults are more susceptible to neutropenia due to age-related changes in the immune system and the higher prevalence of chronic diseases, there is a greater demand for neutropenia treatment. Moreover, the increasing awareness about the importance of early detection and management of neutropenia coupled with improved access to healthcare services and diagnostics will drive the diagnosis rate and treatment-seeking behavior among patients.

The neutropenia treatment market is segmented into treatment type, drug type, route of administration, indication, distribution channel, and region.

By indication, the industry size from the idiopathic neutropenia segment will gain significant traction at 4% CAGR during 2024-2032, characterized by the decrease in neutrophil counts without an identifiable cause. As the underlying cause remains unclear, there is a growing emphasis on symptom management and supportive care to alleviate the risk of infections and improve the quality of life of patients. Additionally, advancements in medical research and understanding of the immune system have led to the development of targeted therapies and immunomodulatory agents that show promise in managing idiopathic neutropenia effectively.

Based on drug type, the neutropenia treatment market from the biosimilar drugs segment is anticipated to witness 4.8% CAGR throughout 2024 and 2032, as they offer cost-effective alternatives to originator biologic drugs. With healthcare systems worldwide seeking to contain costs without compromising patient care, the affordability and availability of biosimilar drugs is driving their adoption in neutropenia treatment regimens. Additionally, biosimilar drugs undergo rigorous regulatory scrutiny to demonstrate comparable efficacy and safety profiles to their reference biologics, instilling confidence among healthcare providers and patients.

Asia Pacific neutropenia treatment industry size is anticipated to grow at 4.8% CAGR over 2024-2032, attributed to the rapidly expanding population and increasing prevalence of infectious diseases. Improving healthcare infrastructure and rising healthcare expenditure in countries like China and India have enhanced the access to neutropenia diagnosis and treatment. The growing awareness about neutropenia among healthcare professionals and patients coupled with advancements in medical research and treatment options will further stimulate the market expansion in the Asia Pacific region.

Table of Contents

Chapter 1 Methodology & Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2023

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018-2032 ($ Million)

Chapter 6 Market Estimates and Forecast, By Drug Type, 2018-2032 ($ Million)

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2018-2032 ($ Million)

Chapter 8 Market Estimates and Forecast, By Indication, 2018-2032 ($ Million)

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018-2032 ($ Million)

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Million)

Chapter 11 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â